For the Inventor, By the Inventor

Enter assignee name

Rockville, MD, United States of America

Synthetic Biologics, Inc.

Calculating rank

USPTO Granted Patents = 39

% Expired Patents = 2.6

EPO Patents = 11

Forward Citations = 91

Loading Chart...

Loading Chart...

21 inventors (with patents filed for the assignee):

Michael Kaleko (24 out of 63 patents)

Sheila Connelly (20 out of 32 patents)

Pertti Koski (8 out of 11 patents)

4. Ulla Airaksinen (8 out of 12 patents)

5. Katja Valimaki (8 out of 9 patents)

6. Andrew Bristol (5 out of 10 patents)

7. Vincent Wacher (4 out of 8 patents)

8. Christian Furlan Freguia (3 out of 9 patents)

9. Steven Hubert (3 out of 6 patents)

10. Ellen Wagner (3 out of 7 patents)

11. Annalee Nguyen (3 out of 9 patents)

12. Eduardo Padlan (3 out of 3 patents)

13. Jennifer A Maynard (3 out of 11 patents)

14. Mark Pimentel (2 out of 59 patents)

15. Vince Wacher (2 out of 6 patents)

Core Competencies:

Alkaline Phosphatase

Beta-Lactamase

Microbiome Protection

Radiation Disorders

Neurodevelopmental Disorders

Anti-Methanogenic

Carbapenemases

Humanized Antibodies

Improved Properties

Oral Antibiotics

39 patents: Sort by Forward Citations

1. 12691077 - ALKALINE PHOSPHATASE FORMULATIONS AND USES THEREOF (2026-07-28),

2. 12648987 - ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS (2026-06-09),

3. 11542510 - -based production of beta-lactamase (2023-01-03),

4. 11517614 - Microbiome protection from oral antibiotics (2022-12-06),

5. 11338020 - Alkaline phosphatase agents for treatment of neurodevelopmental disorders (2022-05-24),

6. 11253577 - Safe and effective beta-lactamase dosing for microbiome protection (2022-02-22),

7. 11034966 - -based production of beta-lactamase (2021-06-15),

8. 10987410 - Alkaline phosphatase formulations (2021-04-27),

9. 10828260 - Beta-lactamase formulations and uses thereof (2020-11-10),

10. 10792346 - Method and compositions for inhibiting or preventing adverse effects of oral antibiotics (2020-10-06),

11. 10767171 - Beta-lactamases with improved properties for therapy (2020-09-08),

12. 10736871 - Anti-methanogenic lovastatin analogs or derivatives and uses thereof (2020-08-11),

13. 10709773 - Safe and effective beta-lactamase dosing for microbiome protection (2020-07-14),

14. 10584326 - Beta-lactamases with improved properties for therapy (2020-03-10),

15. 10548955 - Carbapenemases for use with antibiotics for the protection of the intestinal microbiome (2020-02-04),

Company Overview

Synthetic Biologics, Inc. is a biotechnology company based in Rockville, Maryland, focused on developing innovative therapeutics for the treatment of serious diseases. The company specializes in synthetic biology and microbiome-based therapies, aiming to address unmet medical needs through its proprietary technologies. By leveraging advanced research in microbiome modulation and other biological processes, Synthetic Biologics seeks to create effective solutions for conditions such as gastrointestinal disorders and infections.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

39 Patents

#18 in Rockville, MD

#104 in Maryland

#8,835 in US

#17,475 in the World

Rockville, MD, United States of America

Synthetic Biologics, Inc.

Forward Citations = 91

21 inventors:

Michael Kaleko (24 out of 63 patents)

Sheila Connelly (20 out of 32 patents)

Pertti Koski (8 out of 11 patents)

4. Ulla Airaksinen (8 out of 12 patents)

5. Katja Valimaki (8 out of 9 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Synthetic Biologics, Inc.. Retrieved from https://idiyas.com/company/synthetic-biologics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…